GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (NYSE:ZTS) » Definitions » Asset Turnover

Zoetis (Zoetis) Asset Turnover : 0.16 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Zoetis Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Zoetis's Revenue for the three months ended in Dec. 2023 was $2,213 Mil. Zoetis's Total Assets for the quarter that ended in Dec. 2023 was $14,196 Mil. Therefore, Zoetis's Asset Turnover for the quarter that ended in Dec. 2023 was 0.16.

Asset Turnover is linked to ROE % through Du Pont Formula. Zoetis's annualized ROE % for the quarter that ended in Dec. 2023 was 41.69%. It is also linked to ROA % through Du Pont Formula. Zoetis's annualized ROA % for the quarter that ended in Dec. 2023 was 14.79%.


Zoetis Asset Turnover Historical Data

The historical data trend for Zoetis's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zoetis Asset Turnover Chart

Zoetis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.53 0.57 0.56 0.59

Zoetis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.14 0.16 0.15 0.16

Competitive Comparison of Zoetis's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zoetis's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zoetis's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Zoetis's Asset Turnover falls into.



Zoetis Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Zoetis's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=8544/( (14925+14286)/ 2 )
=8544/14605.5
=0.58

Zoetis's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=2213/( (14106+14286)/ 2 )
=2213/14196
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Zoetis  (NYSE:ZTS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Zoetis's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=2100/5037.5
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(2100 / 8852)*(8852 / 14196)*(14196/ 5037.5)
=Net Margin %*Asset Turnover*Equity Multiplier
=23.72 %*0.6236*2.8181
=ROA %*Equity Multiplier
=14.79 %*2.8181
=41.69 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Zoetis's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=2100/14196
=(Net Income / Revenue)*(Revenue / Total Assets)
=(2100 / 8852)*(8852 / 14196)
=Net Margin %*Asset Turnover
=23.72 %*0.6236
=14.79 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Zoetis Asset Turnover Related Terms

Thank you for viewing the detailed overview of Zoetis's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Zoetis (Zoetis) Business Description

Address
10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Executives
Roxanne Lagano officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Kristin C Peck officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Heidi C. Chen officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Robert J Polzer officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Soria Ester Banque officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Rimma Driscoll officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Jamie Brannan officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Vanessa Broadhurst director ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Willie M Reed director C/O ZOETIS, 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Nicholas Ashton officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Roman Trawicki officer: Executive Vice President C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07932
Glenn David officer: SVP and Acting CFO C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Astorga Jeannette Ferran officer: Executive Vice President C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Catherine A. Knupp officer: Executive Vice President C/O ZOETIS INC., 100 CAMPUS DRIVE, FLORHAM PARK NJ 07940
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005

Zoetis (Zoetis) Headlines

From GuruFocus

Q3 2021 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2022 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Zoetis Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 01-23-2024

Q2 2023 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2021 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2023 Zoetis Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Zoetis Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-23-2024